Qiming Spotlight | Over 10 Qiming Venture Partners Portfolio Companies Named to Star 100 · 2025 China AI Industry Wave Makers List
The rankings confirm AI technology's evolution from technical exploration to the deep waters of industry application, while also showcasing Chinese companies' technical strength and growth potential.
Recently, the Star 100 · 2025 China AI Industry Wave-Riders list was officially unveiled. Covering five major domains — AI chips, large AI models, AI Infra, AI applications, and embodied artificial intelligence — the list captures the evolution of AI technology from exploratory research into the deeper waters of industrial application, while showcasing the technical capabilities and growth potential of Chinese enterprises.
Qiming Venture Partners portfolio companies Axera, Biren Technology, Houmo AI, StepFun, Unisound, Zhipu AI, Infinigence AI, Shengshu Technology, Zhihu (NYSE: ZH, 02390.HK), Mech-Mind Robotics, and Galaxy Universal were named to the list.
Axera, Biren Technology, Houmo AI
(AI chips)
StepFun, Unisound, Zhipu AI
(Large AI models)
Infinigence AI
(AI Infra)
Shengshu Technology · Vidu
Zhihu · Zhihu Direct Answer
(AI applications)
Mech-Mind Robotics, Galaxy Universal
(Embodied Artificial Intelligence)
Selected for
Star 100 · 2025 China AI Industry Wave-Riders List
· Star 100 · 2025 China AI Industry Wave-Riders List
The evaluation centered on four core dimensions: product strength, commercial strength, financing strength, and brand strength. Product strength encompasses product performance, technological innovation, R&D investment, feature richness, and user experience. Commercial strength covers user base, business model, revenue scale, revenue growth rate, and profitability. Financing strength includes recent funding scale and future financing plans. Brand strength comprises brand recognition, industry influence, benchmark case studies, and active user numbers. Jazzyear also assessed performance across strategic foresight, social value, and ecosystem contribution.
In 2025, artificial intelligence is rapidly evolving from technological exploration to scaled industrial application, becoming a core engine driving global economic growth and digital-intelligent transformation. Led by breakthroughs in large model technology, cutting-edge fields such as multimodal AI and embodied intelligent robotics are accelerating toward commercialization.
Chinese AI companies have built distinctive advantages through original breakthroughs and scaled deployment capabilities. Through architectural innovation, they have carved out alternative technical paths and established competitiveness in critical areas including algorithmic energy efficiency and multimodal fusion.
Source | Jazzyear
Past Coverage
Qiming Honors | Qiming Venture Partners and Portfolio Companies Named to 2023-2024 China Technology Industry Investment List Morning Star | Multiple Qiming Venture Partners Portfolio Companies Win Touzijia 2025 Robotics Industry Conference · Gold Flint Award Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including ChinaVenture 2024 Top 5 Best VC Firms
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.